Arizona State Retirement System Sells 246 Shares of LivaNova PLC (NASDAQ:LIVN)

Arizona State Retirement System decreased its position in LivaNova PLC (NASDAQ:LIVN) by 1.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 15,063 shares of the company’s stock after selling 246 shares during the quarter. Arizona State Retirement System’s holdings in LivaNova were worth $779,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. Pacer Advisors Inc. grew its stake in shares of LivaNova by 80.8% in the 4th quarter. Pacer Advisors Inc. now owns 8,102 shares of the company’s stock valued at $419,000 after buying an additional 3,621 shares in the last quarter. SG Americas Securities LLC lifted its holdings in LivaNova by 18.9% in the 4th quarter. SG Americas Securities LLC now owns 37,611 shares of the company’s stock worth $1,946,000 after purchasing an additional 5,990 shares during the last quarter. Diversified Trust Co acquired a new stake in LivaNova in the 4th quarter worth approximately $626,000. Vanguard Group Inc. lifted its holdings in LivaNova by 6.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,770,277 shares of the company’s stock worth $93,612,000 after purchasing an additional 100,133 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky lifted its holdings in LivaNova by 93.6% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 18,370 shares of the company’s stock worth $971,000 after purchasing an additional 8,879 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

LIVN has been the subject of several analyst reports. Needham & Company LLC restated a “buy” rating and issued a $72.00 target price on shares of LivaNova in a report on Wednesday, March 20th. Robert W. Baird upped their price target on LivaNova from $56.00 to $62.00 and gave the stock a “neutral” rating in a report on Thursday, February 22nd. Barclays upped their price target on LivaNova from $57.00 to $61.00 and gave the stock an “equal weight” rating in a report on Monday, February 26th. StockNews.com lowered LivaNova from a “buy” rating to a “hold” rating in a report on Wednesday. Finally, Mizuho reiterated a “buy” rating and set a $75.00 price target on shares of LivaNova in a report on Wednesday, March 27th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $64.40.

LivaNova Stock Performance

Shares of NASDAQ LIVN opened at $51.87 on Thursday. The business has a fifty day simple moving average of $53.51 and a 200 day simple moving average of $50.53. The company has a current ratio of 2.95, a quick ratio of 2.51 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $2.80 billion, a price-to-earnings ratio of 162.10 and a beta of 0.89. LivaNova PLC has a one year low of $42.75 and a one year high of $59.86.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, February 21st. The company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.10. LivaNova had a return on equity of 12.23% and a net margin of 1.53%. The firm had revenue of $310.10 million for the quarter, compared to analysts’ expectations of $287.65 million. During the same period in the prior year, the business posted $0.81 earnings per share. The business’s revenue was up 12.8% compared to the same quarter last year. Sell-side analysts expect that LivaNova PLC will post 3.01 EPS for the current year.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.